Lauriad for Oral Thrush
People with oral candidiasis will take either Lauriad (miconazole) tablets once a day or clotrimazole troches 5x a day for 2 weeks. Participants must be 18 or older and be on stable HAART for at least 2 months.
Transacin (NGX-4010) for Peripheral Neuropathy
People with HIV who have peripheral neuropathy will use either Transacin (capsaicin) patches or placebo patches for 30 or 60 minutes a day for 3 months. Participants must be 18 or older and have had pain in both feet for at least 2 months.
Pregabalin for Peripheral Neuropathy
People with HIV who have peripheral neuropathy will take either pregabalin (Lyrica) or a placebo (dummy pill) for 3 months. Participants must be 18 or older and have had pain in their hands or feet for at least 3 months.
KP-1461 for Resistant HIV
People with HIV that is resistant to at least 3 of the 4 classes of HIV drugs will stop all HIV drugs for 6 weeks and then take KP-1461 (an experimental NRTI) or a placebo pill twice a day for 2 weeks. Participants must be 18 to 60 years old, have a CD4 count above 100 and a viral load between 2,500 and 50,000.
IMPACT: Reyataz Resistance
People who have developed resistance to Reyataz will come in for one day of blood tests to study the I50L mutation.
For the above trials, contact Dr. Douglas Mendez at 212-924-3934 ext. 126 or Dr. Yuriy Akulov at ext. 124.
HIV Treatment Decision-Making Study
African-Americans who have not taken HIV drugs will complete a one-hour survey on a laptop computer and receive a $25 debit card. Participants must be 18 or older. Contact Perion Smith at 212-924-3934 ext. 105.
DUET: TMC 114 & 125 for Drug-Resistant HIV (Closed to Enrollment)
People who are resistant to PIs and NNRTIs will take TMC125 (a new NNRTI) or a placebo (dummy) pill. Everyone will also take TMC114 (a new PI) with Norvir and other anti-HIV drugs. Participants must be 18 or older and have a viral load over 5,000.
TH9507 for Lipodystrophy (Closed to Enrollment)
People who have excess abdominal fat and who are taking anti-HIV drugs will take either TH9507 (an experimental growth hormone releasing factor) or a placebo for 26 weeks.
Maraviroc for Drug-Resistant HIV (Closed to Enrollment)
People who have taken anti-HIV drugs from three of the four classes of drugs will either take maraviroc (an experimental HIV attachment inhibitor) or placebo with an optimized regimen of anti-HIV drugs for 11 months.